Clinical Trial Update: Individualization of the Immunological Risk Based on Selective Biomarkers in Living-donor Renal Recipients [Phase 4]

View source ↗

Summary

Phase 4 trial update exploring individualization of immunological risk using selective biomarkers in living-donor kidney transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Rejection
• Kidney Transplant Failure

Snippet

Sponsor: ORIOL BESTARD | Conditions: Kidney Transplant Failure and Rejection | Phase 4 | Status: UNKNOWN